{"id":"W4408140991","doi":"10.1016/s2352-3018(24)00344-8","title":"Safety of combined long-acting injectable cabotegravir and long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study","year":2025,"lang":"en","type":"article","venue":"The Lancet HIV","topic":"HIV-related health complications and treatments","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute of Child Health and Human Development; National Institute of Allergy and Infectious Diseases; National Institute of Mental Health; National Institutes of Health","keywords":"Rilpivirine; Medicine; Human immunodeficiency virus (HIV); Pharmacology; Dolutegravir; Maximum tolerated dose; Phases of clinical research; Oncology; Adverse effect; Virology; Internal medicine; Antiretroviral therapy; Viral load; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002337762,0.0008792409,0.00206952,0.0004811959,0.0002837451,0.001205105,0.0008785521,0.00160651,0.003407762],"category_scores_gemma":[0.00217334,0.000599503,0.00176584,0.0003626768,0.001013755,0.001258981,0.0003532206,0.002682029,0.0006110045],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009856325,"about_ca_system_score_gemma":0.00093561,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007508004,"about_ca_topic_score_gemma":0.001443308,"domain_scores_codex":[0.9989331,0.0006207063,0.00005513023,0.0001424468,0.0001329547,0.000115661],"domain_scores_gemma":[0.9984065,0.0005564162,0.000374594,0.0001176375,0.0001003839,0.000444625],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8994337,0.02345855,0.00642657,0.00074577,0.002712501,0.00009954701,0.0002125963,0.0004257857,0.008807534,0.0001419511,0.0006026623,0.05693286],"study_design_scores_gemma":[0.5527448,0.4248917,0.01669153,0.0001053619,0.001883047,0.0001721162,0.0001426311,0.0006058613,0.001515066,0.0001899073,0.001017766,0.00004006072],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9954408,0.002580175,0.0002153733,0.0001467612,0.00007483472,0.0004270158,0.0003708565,0.00002712434,0.0007169446],"genre_scores_gemma":[0.996176,0.001183818,0.0006619584,0.0003158425,0.0001306397,0.0003791878,0.000433366,0.00001400084,0.0007051012],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003407762,"threshold_uncertainty_score":0.01236343,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06715696422115511,"score_gpt":0.3883279035400025,"score_spread":0.3211709393188473,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}